161529-14-2

Usage

Uses

Used in Pharmaceutical Synthesis:
FMOC-(S)-3-AMINO-4-HYDROXYBUTANOIC ACID T-BUTYL ESTER is used as a precursor for the synthesis of pharmaceutical compounds. Its unique structure allows for the creation of complex molecules that can be used in the development of new drugs.
Used in Peptide Chemistry:
In the field of peptide chemistry, FMOC-(S)-3-AMINO-4-HYDROXYBUTANOIC ACID T-BUTYL ESTER is used as a building block for the assembly of peptide chains. Its presence in solid-phase peptide synthesis facilitates the stepwise construction of peptides, enhancing the efficiency and accuracy of the process.
Used as a Chiral Auxiliary:
FMOC-(S)-3-AMINO-4-HYDROXYBUTANOIC ACID T-BUTYL ESTER also serves as a chiral auxiliary in various organic reactions. Its stereochemistry plays a crucial role in the selectivity and outcome of asymmetric reactions, making it an indispensable tool in the synthesis of enantiomerically pure compounds.
Used in Organic Synthesis:
In organic synthesis, FMOC-(S)-3-AMINO-4-HYDROXYBUTANOIC ACID T-BUTYL ESTER is employed as a versatile intermediate. Its ability to participate in a wide range of reactions makes it suitable for the synthesis of diverse organic compounds, including those with potential applications in materials science, agrochemicals, and other specialized fields.

Upstream product

• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 71989-14-5 N-(9-fluorenylmethoxycarbonyl)-4-O-tert-butyl-D-aspartic acid 
• 543-27-1 isobutyl chloroformate 
• 183673-66-7 N-Fmoc-amino-(4-N-Boc-piperidinyl)carboxylic acid 

Downstream Products

• 406233-30-5 (R)-3-(9H-fluoren-9-ylmethyloxycarbonylamino)-4-phenylsulfanylbutyric acid tert-butyl ester 
• 1619923-60-2 (R)-3-(((9H-fluoren-9-yl)methoxy)carbonylamino)-4-(2-fluorophenylthio)butanoic acid 
• 1619923-54-4 (R)-(9H-fluoren-9-yl)methyl 4-oxo-1-(phenylthio)butan-2-ylcarbamate 
• 1244724-97-7 (R)-3-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-4-(phenylthio)butanoic acid 
• 406233-32-7 (R)-3-(2-nitro-4-sulfamoylphenylamino)-4-phenylsulfanylbutyric acid tert-butyl ester 

Relevant academic research and scientific papers

PEPTIDE-OLIGOUREA HYBRID COMPOUNDS

The present description relates to peptidomimetic foldamers, and their synthesis. In particular, the description provides peptide-amino urea hybrid peptidomimetic foldamers comprising an alpha amino acid peptide portion and an oligourea portion.

METHOD FOR PREPARING SULFONAMIDES DRUGS

Provided is a method for preparing sulfonamides which are inhibitors of Bcl-2/ Bcl-xL, comprising the compound (3R)-1-(3-(4-(4-(4-(3-(2-(4-chlorophenyl) -1-isopropyl-4-methylsulfonyl-5-methyI-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yI)-phenylam inosulf

Process for preparing sulfonamide compounds

The invention relates to a process for preparing sulfonamide compounds. The sulfonamide compound is an inhibitor of Bcl-2/Bcl-xL and is prepared from a compound (3R)-1-(3-(4-(4-(4-(3-(2-(4-chlorphenyl)-1-isopropyl-4-methylsulfonyl-5-methyl-1H-pyrrole-3-yl

PROCESS FOR PREPARING SULFONAMIDE COMPOUNDS

Provided are a process for preparing a sulfonamide compound which is an inhibitor of Bcl-2/Bcl-xL, including the compound (3R) -1- (3- (4- (4- (4- (3- (2- (4-chlorophenyl) -1-isopropyl-4-methylsulfonyl-5-methyl-1H-pyrrol-3-yl) -5-fluorophenyl) piperazine

iSPAAC: Isomer-Free Generation of a Bcl-xL-Inhibitor in Living Cells

Strain-promoted azide–alkyne cycloadditions (SPAAC) have proven extremely useful for labeling of biomolecules, but typically produce isomeric mixtures. This is not appropriate for the formation of bioactive molecules in living cells. Here, the first use o

APOPTOSIS-INDUCING AGENTS

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti apoptotic Bcl-xL protein.

Profiling small molecule inhibitors against helix-receptor interactions: The Bcl-2 family inhibitor BH3I-1 potently inhibits p53/hDM2

We validate a practical methodology for the rapid profiling of small molecule inhibitors of protein-protein interactions. We find that a well known BH3 family inhibitor can potently inhibit the p53/hDM2 interaction.

BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 or Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which are expressed anti-apoptotic Bcl-2 protein.

DMSO-aided o-iodoxybenzoic acid (IBX) oxidation of Fmoc-protected amino alcohols

A fast and highly convenient procedure for the formation of Fmoc-protected amino aldehydes from the corresponding alcohols using 1.1 equiv. of IBX in the presence of dimethylsulfoxide (DMSO) is discussed. This procedure leads to the clean synthesis of Fmo

Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo

Development of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bcl-XL function, is described. Lead compounds generated by NMR screening and directed parallel synthesis displayed sub-μM binding but were strongly deactivated in the presence of serum. The dominant component of serum deactivation was identified as domain III of human serum albumin (HSA); NMR solution structures of inhibitors bound to both Bcl-X L and HSA domain III indicated two potential optimization sites for separation of affinities. Modifications at both sites resulted in compounds with improved Bcl-XL binding and greatly increased activity in the presence of human serum, culminating in 73R, which bound to Bcl-XL with a Ki of 0.8 μM. In a cellular assay 73R reversed the protection afforded by Bcl-XL overexpression against cytokine deprivation in FL5.12 cells with an EC50 of 0.47 μM. 73R showed little effect on the viability of the human non small cell lung cancer cell line A549. However, consistent with the proposed mechanism, 73R potentiated the activity of paclitaxel and UV irradiation in vitro and potentiated the antitumor efficacy of paclitaxel in a mouse xenograft model.